The mechanism of action of enkephalinase inhibitors is mainly to exert its drug effect by inhibiting the activity of enkephalinase. Enenkephalinase is an enzyme that can degrade endogenous substances such as enkephalin, and enkephalin has important physiological functions in medical and biochemical fields, such as inhibiting neuronal activity, reducing the sensitivity of nerve cells to noxious stimuli, and regulating immune response.
What are enkephalinase and enkephalinase inhibitors?
Enkephalinase, also known as neutral endopeptidase, is a metallopeptidase located on the cell membrane that is expressed in the central nervous system, kidneys, peripheral nervous system, and endothelial cells of blood vessels. Its soluble form exists in blood, cerebrospinal fluid, and amniotic fluid. Enkephalinase can affect various bioactive peptides, including natriuretic peptide, bradykinin, adrenomedullin, vasopressin, glucagon, enkephalin, oxytocin, gastrin, endothelin-1, and vasoactive peptides. And the related enkephalin enzyme inhibitors can precisely reduce bradykinin catabolism, which has cardioprotective functions, thus benefiting heart failure patients. Meanwhile, enkephalin inhibitors can lower blood pressure by protecting the degradation of natriuretic peptide enzymes, balancing vasodilation and vasoconstriction.
What are the representative products of enkephalinase inhibitors?
ARNI stands for angiotensin receptor enkephalinase inhibitor, with the representative drug being sacubitril valsartan sodium. It is commonly used in clinical practice for the treatment of chronic heart failure with reduced ejection fraction. This product is a composite product that contains sacubitril, which can inhibit enkephalinase, increase the level of natriuretic peptide in the blood circulation, effectively counteract the renin-angiotensin system and sympathetic nervous system activation, and has the effects of sodium excretion, drainage, and vasodilation. It can relieve left ventricular remodeling, alleviate discomfort symptoms such as chest tightness and palpitations.
The valsartan contained in this drug can inhibit angiotensin receptors, have a blood pressure lowering effect, alleviate left ventricular hypertrophy caused by hypertension, improve the long-term prognosis of heart failure caused by hypertension, and have significant changes in the symptoms of heart failure with hypertension.
What are the issues with long-term use of LCZ696?
ARNI is composed of angiotensin II type 1 receptor (AT1 receptor) blockers and enkephalinase inhibitors. ARNI is more effective in controlling hypertension than renin angiotensin aldosterone inhibitors alone. The combination of the two forms the eutectic complex LCZ696, which exerts a synergistic effect. However, it should be noted that there is considerable controversy over the potential side effects of long-term use of LCZ696 on the human body, including vascular edema, cancer, bronchitis, inflammation, and Alzheimer's disease. The most controversial aspect is its impact on neurological function. There are reports indicating that LCZ696 can exert cardioprotective effects at least to some extent by inhibiting the degradation of bradykinin. However, an increase in bradykinin levels not only increases the risk of vascular edema, but also can cause the accumulation of beta amyloid protein to form neuroinflammatory plaques, thereby impairing cognitive function.
New exploration of enkephalinase inhibitors and cognitive impairment!
The most striking feature of Alzheimer's disease is the accumulation of β -amyloid protein in some areas of the brain responsible for memory and cognitive function, which forms inflammatory plaques, and the neurofibrillary tangles formed by excessive phosphorylation of Tau protein to ensure normal brain function, which leads to cortical shrinkage, massive loss of neurons in brain areas and abnormal synaptic function, resulting in cognitive impairment of patients. Enenkephalinase is the most important enzyme to degrade β -amyloid protein. enkephalinase inhibitors can reduce the rate of degradation and clearance of β-amyloid, increase the accumulation of β-amyloid, promote the formation of extracellular neuroinflammatory plaques, and lead to the damage of brain neurons and endothelial cells. Sacubitril (AHU-377) is one of the active components of Sacubitril Valsartan Sodium (LCZ 696), and its mechanism may lead to the increase of β -amyloid level in the brain. Although some existing preclinical data about the effect of LCZ696 on β -amyloid accumulation showed promising safety results, some studies also showed that the expression of enkephalinase genes and proteins in the brain of patients with Alzheimer's disease decreased significantly, and the epidemiological study of dementia-related diseases in elderly patients with heart failure suggested that the incidence of dementia in patients with heart failure was high. The onset time of Alzheimer's disease is more than several decades, and the follow-up time of existing clinical trials is relatively short, so the potential effects of this drug on memory and cognitive function need longer research. In a word, further research is needed to explore enkephalinase inhibitors's safety of cognitive function.
Disclaimer: The information published on this website comes from the internet, which does not mean that this website agrees with its views or confirms the authenticity of the content. Please pay attention to distinguish it. In addition, the products provided by our company are only used for scientific research. We are not responsible for the consequences of any improper use.
If you are interested in our products, or have critical suggestions on our articles or are not completely satisfied with the products received, Please also contact us via Email :sales6@faithfulbio.com ; Our team is committed to ensuring the complete satisfaction of customers.

